Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pure Bioscience ( (PURE) ) has provided an update.
Pure Bioscience, Inc. held its Annual Meeting of Stockholders on February 17, 2026, with approximately 66% of outstanding shares represented, and shareholders elected all seven director nominees with overwhelming majorities to serve until the next annual meeting. Investors also approved, on an advisory basis, the executive compensation program and ratified Weinberg & Company, P.A. as the independent auditor for the fiscal year ending July 31, 2026, signaling broad support for current governance and leadership.
In a key capital-structure move, shareholders voted to amend the company’s Certificate of Incorporation to increase authorized common stock from 200 million to 250 million shares, a step that provides added flexibility for future financing, equity compensation, or strategic transactions. No additional items were brought to a vote, underscoring that the meeting primarily reinforced existing governance arrangements while expanding the company’s capacity to issue new equity as needed.
The most recent analyst rating on (PURE) stock is a Hold with a $0.06 price target. To see the full list of analyst forecasts on Pure Bioscience stock, see the PURE Stock Forecast page.
Spark’s Take on PURE Stock
According to Spark, TipRanks’ AI Analyst, PURE is a Neutral.
The score is weighed down primarily by weak financial fundamentals—ongoing losses, negative free cash flow, and a high-risk balance sheet with negative equity. Technicals also remain bearish with the price below key moving averages and negative MACD. Valuation offers limited support because the company is unprofitable (negative P/E) and no dividend yield is provided.
To see Spark’s full report on PURE stock, click here.
More about Pure Bioscience
Pure Bioscience, Inc. is a specialty chemicals company focused on antimicrobial solutions, developing and commercializing disinfectant and food safety products based on proprietary technologies. Its offerings target contamination control and hygiene in sectors such as food processing, healthcare, and institutional facilities, aiming to improve safety standards and regulatory compliance for customers.
Average Trading Volume: 41,072
Technical Sentiment Signal: Strong Sell
Current Market Cap: $6.27M
Learn more about PURE stock on TipRanks’ Stock Analysis page.